Curanex Pharmaceuticals Approves Reverse Stock Split to Avoid Delisting, Adopts New Equity Incentive Plan

summarizeSummary

Curanex Pharmaceuticals' majority stockholders approved a reverse stock split (1:10 to 1:50) to regain Nasdaq compliance and adopted a new equity incentive plan authorizing up to 5.7 million shares, signaling significant potential dilution.

check_boxKey Events · Corporate Governance and Compliance · CURX

• Reverse Stock Split Approved

  Majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50. The Board has discretionary authority to determine the exact ratio and timing. This action is primarily aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement by the November 2, 2026 deadline. The company is currently trading near its 52-week low of $0.262.

• New Equity Incentive Plan Adopted

  The 2026 Equity Incentive Plan was adopted, authorizing the issuance of up to 5,700,000 shares of Common Stock or options. This plan also includes an annual evergreen provision allowing for an increase of up to 4% of outstanding shares each year. Based on current outstanding shares, the initial 5.7 million shares represent approximately 20.1% potential dilution for existing shareholders.

• Nasdaq Compliance Deadline

  The company previously received an extension until November 2, 2026, to regain compliance with the Nasdaq minimum bid price rule. The reverse stock split is a direct measure to address this critical listing requirement.

auto_awesomeAnalysis · CURX · Life Sciences

Curanex Pharmaceuticals, a micro-cap company trading near its 52-week low, has taken critical steps to address its Nasdaq listing compliance and future compensation needs. The approval of a reverse stock split, with a wide range of 1-for-10 to 1-for-50, is a direct response to the Nasdaq minimum bid price requirement, which the company must meet by November 2, 2026, to avoid delisting. While necessary for continued listing, reverse splits are often viewed negatively by the market and carry risks of further price decline and reduced liquidity. Concurrently, the adoption of a new equity incentive plan, authorizing up to 5.7 million shares initially and an annual evergreen increase of up to 4% of outstanding shares, represents significant potential dilution for existing shareholders, especially given the company's reported accelerated cash burn and wider Q1 loss.